Literature DB >> 22108569

Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia.

Hartmut Bertz1, Alexandros Spyridonidis, Gabriele Ihorst, Monika Engelhardt, Carsten Grüllich, Ralph Wäsch, Reinhard Marks, Jürgen Finke.   

Abstract

Peripheral blood stem cells (PBSCs) are increasingly used as the graft source in allogeneic hematopoietic cell transplantation. We compared long-term outcome after unrelated donor transplantation of 85 consecutive patients with acute myelogenous leukemia or myelodysplastic syndrome regarding disease status (early disease [CR1, refractory anemia); n = 25 and advanced/active disease [>CR1, >refractory anemia]; n = 60) who were treated with conventional conditioning regimens followed by bone marrow (BM) or PBSC grafts. Graft-versus-host disease prophylaxis consisted mainly of cyclosporine A, short-course methotrexate, and anti-T-lymphocyte globulin. After a median follow-up of 118 months (68-174), the 10-year event-free survival rate after peripheral blood stem cell transplantation (PBSCT) was 54.8% (95% confidence interval [CI], 39.7%-69.8%), and after bone marrow transplantation (BMT), it was 27.9% (14.5%-41.3%; P < .004). In the advanced/active disease group, the 10-year event-free survival rate after PBSCT was 50% (30.8%-69.2%), and after BMT, it was 23.5% (9.3%-37.8%; P < .007). Non relapse mortality was less after PBSCT than BMT (14.3% vs 30.2%), respectively. In multivariate Cox regression analysis, PBSCT showed a better overall survival (OS; hazard ratio [HR], 0.43; 95% CI, 0.23-0.79; P = .007) compared to BMT; unfavorable/unknown prognostic impact cytogenetic abnormalities were an adverse factor for all patients (HR, 2.202; 95% CI, 1.19-4.06; P = .011). In patients with advanced disease, the use of PBSCs showed a significant favorable outcome via multivariate analysis (HR, 0.49; 95% CI, 0.24-0.99; P = .046). Outcome of acute myelogenous leukemia/myelodysplastic syndrome after unrelated hematopoietic cell transplantation is adversely affected by cytogenetic abnormalities and state of remission at hematopoietic cell transplantation. PBSC as a graft source has a significant favorable influence on survival.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22108569     DOI: 10.1016/j.bbmt.2011.11.017

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  4 in total

Review 1.  Personalized nanomedicine advancements for stem cell tracking.

Authors:  Miroslaw Janowski; Jeff W M Bulte; Piotr Walczak
Journal:  Adv Drug Deliv Rev       Date:  2012-07-20       Impact factor: 15.470

2.  Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.

Authors:  G Andreola; M Labopin; D Beelen; P Chevallier; R Tabrizi; A Bosi; M Michallet; S Santarone; G Ehninger; E Polge; D Laszlo; C Schmid; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-09-21       Impact factor: 5.483

3.  Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.

Authors:  Daniel Fuerst; Carlheinz Mueller; Dietrich W Beelen; Christine Neuchel; Chrysanthi Tsamadou; Hubert Schrezenmeier; Joannis Mytilineos
Journal:  Haematologica       Date:  2015-11-26       Impact factor: 9.941

4.  PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL.

Authors:  S-H Shin; J-H Yoon; S-A Yahng; S-E Lee; B-S Cho; K-S Eom; Y-J Kim; H-J Kim; C-K Min; S-G Cho; D-W Kim; J-W Lee; W-S Min; C-W Park; S Lee
Journal:  Bone Marrow Transplant       Date:  2014-03-24       Impact factor: 5.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.